+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 242 Actively Recruiting clinical trials

S

Actively Recruiting

Researchers are evaluating whether a structured training program for intensive care unit ICU staff can reduce health problems known as post-intensive care syndrome PICS in adults after they leave the hospital. PICS includes new or worsened physical, thinking, or emotional difficulties following serious illness, which can affect daily life, independence, memory, mood, and overall quality of life. This multicenter study compares patients treated before and after ICU staff training, focusing on whether the training reduces PICS three months after hospital discharge. The study also compares standard training on the ABCDEF care bundle with an expanded A-Z bundle that includes additional care elements like nutrition, sleep, infection prevention, safety, and psychological support. The study involves a cluster-randomized design where entire ICUs are assigned to receive training on either the standard ABCDEF bundle or the expanded A-Z bundle. The training program for ICU staff includes a month-long online course with educational materials, checklists, pocket guides, and visual reminders, plus face-to-face sessions to reinforce learning. After training, ICUs continue usual care while researchers track how often the trained care practices are followed during patients ICU stays, up to 21 days or until discharge or death. Follow-up visits for patients occur at 1, 3, 6, and 12 months after hospital discharge. Participants are adults who stay in the ICU for at least 48 hours and leave the hospital alive. They will undergo tests and questionnaires on physical health, memory, mood, and quality of life during follow-up visits. Data collection includes ICU care details and patient outcomes, monitored using electronic forms with quality checks. The main outcome measured is the number of participants who develop PICS three months after discharge. Secondary outcomes include adherence to care bundles, incidence of delirium, and quality of life assessments at various timepoints. The study runs until 2028 and maintains ethical and data protection standards throughout.

Age: 18Years +All GendersPhase Not Applicable
2 locations
P

Actively Recruiting

Researchers are evaluating the combination of CGT9486 and sunitinib compared to sunitinib alone in patients with locally advanced, unresectable, or metastatic Gastrointestinal Stromal Tumors GIST. This Phase 3, open-label international trial involves multiple parts, including dose confirmation, drug interaction assessments, and efficacy comparisons. The study also includes substudies focusing on drug-drug interaction potential and first-line treatment in patients with specific genetic mutations KIT exon 9. Approximately 482 patients will participate across these parts.

Age: 18Years +All GendersPhase 3
126 locations
E

Actively Recruiting

Healthy Volunteer

Researchers are evaluating MammoWave, a device that uses low-power microwaves instead of X-rays, for early breast cancer detection in women aged 45 to 74. This prospective, multicenter clinical investigation aims to confirm that MammoWave achieves sensitivity greater than 75% and specificity greater than 90% for breast cancer detection among 10,000 volunteers undergoing regular screening programs. The study compares MammoWave results with conventional breast examination methods including mammograms and other radiological or histological tests. Participants will undergo both the standard breast screening exams and the MammoWave exam. The MammoWave exam involves lying prone on a bed while the device collects microwave data from both breasts over about 8 minutes. Data processing uses a special imaging algorithm to produce microwave images and classification results indicating suspicious or non-suspicious findings. The study device contains the same hardware as a CE-marked version but uses updated software. During the study, participants will have conventional breast exams along with the MammoWave exam. Researchers will evaluate MammoWaves sensitivity and specificity during the procedure and analyze detection rates, recall rates, and positive predictive values at baseline. Volunteers will also complete satisfaction questionnaires. The study will monitor breast cancer detection by histological type, size, and breast density. The trial is expected to run until December 2026.

Age: 45Years - 74YearsFEMALEPhase Not Applicable
10 locations
P

Actively Recruiting

Researchers are studying MK-7262, a trial medicine designed to lower Lipoproteina Lpa levels in the blood. The study aims to learn about the effects of MK-7262 alone and in combination with another trial medicine called enlicitide, which belongs to a group of medicines that lower low-density lipoprotein cholesterol LDL-C. This Phase 2 clinical trial evaluates the ability of these medicines to reduce Lpa and LDL-C levels and assesses their safety and tolerability. Participants will be randomly assigned to one of four groups MK-7262 with enlicitide, MK-7262 alone, enlicitide alone, or placebo for both medicines. All treatments are given orally once daily for up to approximately 12 weeks. The study is double-blind with placebo controls, and the medicines are taken as coated tablets. The trial monitors effects at specific time points including weeks 8 and 12. During the trial, participants will undergo blood tests to measure changes in Lpa and LDL-C levels from baseline. Researchers will track adverse events and monitor safety for up to about 20 weeks. The primary outcomes include percent changes in Lpa and LDL-C at week 8 and the number of participants experiencing side effects or discontinuing treatment due to side effects. Participation lasts for the treatment period and follow-up assessments.

Age: 18Years +All GendersPhase 2
76 locations
D

Actively Recruiting

Researchers are evaluating a new multi-component score called the Readiness for EXtubation score REXs to predict when ICU patients on invasive mechanical ventilation are ready to be extubated. The process of liberation from mechanical ventilation involves weaning, readiness assessment, and extubation, with success defined as not needing invasive support within 48 hours. This study focuses on developing and analyzing REXs to help clinicians assess extubation readiness more accurately in critically ill patients. The study involves daily screening of ICU patients undergoing weaning from invasive mechanical ventilation. Data collected include clinical parameters such as arterial blood gases, ventilation settings, sedation and agitation scores, heart rate, hemoglobin levels, nutritional status, and cough strength, among others. Clinicians will anonymously enter data into an electronic case report form to develop and evaluate the REXs score. Patients prepared for extubation will have their readiness assessed using this score. Participants will be monitored during their ICU stay, with data collected on extubation success or failure at 24, 48, and 72 hours after extubation. Researchers will also track length of ICU and hospital stays and mortality outcomes. The study uses routine clinical data, with anonymization to protect patient confidentiality. Statistical methods will analyze associations between clinical factors and extubation outcomes to validate the REXs scores predictive ability. The total study duration extends until the end of 2026.

Age: 18Years - 89YearsAll Genders
7 locations
P

Actively Recruiting

Researchers are evaluating IDP-121, a new drug targeting the cMyc protein, in patients with relapsed or refractory blood cancers including multiple myeloma, diffuse large B-cell lymphoma, high-grade B-cell lymphomas, and chronic lymphocytic leukemia. This open-label, multicenter Phase 12 study aims first to find the highest safe dose and recommended dose for further study, then to assess how well patients respond to the drug and how long those responses last. In the Phase 1 dose-escalation phase, patients receive IDP-121 by 4-hour intravenous infusion twice weekly on specific days within 28-day cycles. Doses start low and increase based on safety and tolerance, with monitoring for dose-limiting toxicities during the first treatment cycle. Once the recommended Phase 2 dose is identified, additional patients enter the expansion phase to further assess safety and effectiveness, receiving treatment for up to 12 cycles or until progression or unacceptable side effects. Participants will undergo regular monitoring including blood tests, heart function assessments, and evaluations of their disease status throughout treatment. Researchers will measure outcomes such as overall response rate, duration of response, and progression-free survival. The study allows treatment to continue up to one year, with careful tracking of safety and disease progression, aiming to gather comprehensive data on IDP-121s impact in these blood cancers.

Age: 18Years +All GendersPhase 1Phase 2
11 locations
P

Actively Recruiting

Researchers are evaluating a new medication called VH4524184 for treating adults with HIV-1 who have never received treatment before. This Phase 2b study compares two doses of VH4524184, each taken with the medications emtricitabine and tenofovir alafenamide FTCTAF, against a standard HIV treatment combining dolutegravir and lamivudine DTG3TC. The goal is to collect long-term data on the antiviral activity of VH4524184 and to understand the best dosing for future studies. Participants are assigned to one of several groups one group receives a low dose of VH4524184 plus FTCTAF daily for 12 months, another group receives a high dose of VH4524184 plus FTCTAF daily for 12 months, and a third group takes DTG and 3TC daily for 24 months. After 12 months, those on VH4524184 may continue with a selected dose combined with FTCTAF daily until month 24. All medications are taken orally. During the study, participants attend scheduled visits for assessments including blood tests to measure HIV-1 RNA levels, CD4 T-cell counts, and drug concentrations. Researchers monitor the percentage of participants achieving viral suppression at 12 months and maintain it through 24 months. Safety is closely observed through tracking adverse events until roughly month 36. The total participation time may span up to 36 months to evaluate the long-term effects and safety of the treatments.

Age: 18Years +All GendersPhase 2
123 locations
P

Actively Recruiting

Researchers are studying UGN-104, a new form of UGN-101 also known as JELMYTO, to evaluate its safety and effectiveness for treating low-grade upper tract urothelial cancer LG-UTUC. This phase 3 study focuses on patients with this type of cancer located in the upper urinary tract. The research aims to understand how well UGN-104 works when placed directly into the affected area and to monitor its safety during treatment. Participants will receive UGN-104 once a week for six weeks, totaling six doses. This medication combines mitomycin with a special gel that becomes semi-solid at body temperature, allowing it to stay in the urinary tract longer. After about three months from the first dose, patients undergo evaluation to check for complete response, which includes urine tests and visual exams of the urinary tract. Those who respond completely may receive monthly maintenance doses of UGN-104 for up to 11 months. Patients who do not respond fully complete the study at this point. Throughout the study, participants will have regular clinic visits every three months for up to a year after their initial evaluation or until the cancer returns, worsens, or the patient passes away. Assessments include urine cytology, ureteroscopy, biopsies if needed, and laboratory tests to monitor mitomycin levels and side effects. Researchers will track treatment response duration, safety events, and drug concentrations to better understand the therapy and its effects over time.

Age: 18Years +All GendersPhase 3
79 locations
R

Actively Recruiting

Researchers are evaluating whether the combination of pelabresib and ruxolitinib improves clinical outcomes compared to ruxolitinib alone in adults with primary myelofibrosis, post-polycythemia vera myelofibrosis, or post-essential thrombocythemia myelofibrosis who have not previously received Janus kinase inhibitor therapy. This phase 3 trial aims to assess treatment effects on spleen size and symptom scores using a randomized, double-blind design. Participants receive pelabresib or placebo orally once daily for 14 days in each 21-day cycle alongside continuous twice-daily oral ruxolitinib during the treatment period. The treatment continues until unacceptable side effects, disease progression, or withdrawal. The study includes a screening phase, a safety follow-up lasting about 30 days after last dose, an efficacy follow-up every 12 weeks for those without disease progression, and a survival follow-up with remote visits every 12 weeks for participants who progress or start new therapies. During the study, participants undergo regular assessments including spleen imaging by CT or MRI, laboratory tests, bone marrow biopsies, and symptom questionnaires. Researchers measure spleen response and symptom score changes at 24 weeks and continue monitoring multiple outcomes such as survival, anemia, and quality of life for up to three years. Safety is closely followed during and after treatment to observe any adverse events or late effects.

Age: 18Years +All GendersPhase 3
163 locations
P

Actively Recruiting

Researchers are evaluating AZD0780, an oral PCSK9 inhibitor, in a phase 3 randomized, double-blind, placebo-controlled study to assess its effect on reducing major adverse cardiovascular events in patients with established atherosclerotic cardiovascular disease ASCVD or those at high risk for a first ASCVD event. The study compares AZD0780 with a placebo and is event-driven, focusing on time to first cardiovascular events over approximately 54 months. Participants will be randomly assigned to receive either oral AZD0780 once daily or a matching placebo once daily. The study treatment continues from randomization until the primary analysis censoring date, followed by a study closure visit which marks the final visit for each participant. Background lipid-lowering therapy is maintained and expected to achieve significant LDL cholesterol reduction. The study design includes parallel treatment groups with quadruple masking to ensure unbiased results. During the study, participants attend regular visits for monitoring and assessments over a period that can last up to about 54 months. Researchers will measure the time to first major cardiovascular events including heart attack, stroke, urgent coronary revascularization, cardiovascular death, and other related outcomes. Safety and efficacy are carefully monitored through clinical evaluations, laboratory tests, and patient follow-up until study completion.

Age: 18Years +All GendersPhase 3
1452 locations

1-10 of 242

1